Get started
Author

Sofie F. Isebaert

Observed names: ISEBAERT S, Isebaert, Sofie, S Isebaert, S. Isebaert, Sofie Isebaert
Observed institutions: HOGENT University of Applied Sciences and Arts, Universitair Ziekenhuis Leuven, The Netherlands Cancer Institute, Ghent University, IRCCS Ospedale San Raffaele, KU Leuven
OpenAlex ID: A5009074182
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial
2021 · Linda G. W. Kerkmeijer, Veerle H. Groen, et al. · Journal of Clinical Oncology · 538
PDF
Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer
2020 · Cédric Draulans, Uulke A. van der Heide, et al. · Radiotherapy and Oncology · 181
PDF
Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened
2015 · Annelies Gonnissen, Sofie Isebaert, et al. · Oncotarget · 176
PDF
Multiparametric MRI for prostate cancer localization in correlation to whole‐mount histopathology
2012 · Sofie Isebaert, Laura Van den Bergh, et al. · Journal of Magnetic Resonance Imaging · 170
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial
2018 · Evelyn M. Monninkhof, Juliette W.L. van Loon, et al. · Radiotherapy and Oncology · 125
PDF
Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication
2013 · Annelies Gonnissen, Sofie Isebaert, et al. · International Journal of Molecular Sciences · 111
PDF
Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer
2021 · Veerle H. Groen, Karin Haustermans, et al. · European Urology · 82
Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement
2015 · Laura Van den Bergh, Evelyne Lerut, et al. · Urologic Oncology Seminars and Original Investigations · 80
Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial
2024 · Cédric Draulans, Karin Haustermans, et al. · Radiotherapy and Oncology · 76
PDF
Urethral and bladder dose–effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial
2021 · Veerle H. Groen, Marcel van Schie, et al. · Radiotherapy and Oncology · 66
PDF
Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology
2011 · Sofie Isebaert, Frederik De Keyzer, et al. · European Journal of Radiology · 61
Mycotoxin‐producing Fusarium Species Occurring in Winter Wheat in Belgium (Flanders) During 2002–2005
2008 · Sofie Isebaert, Sarah De Saeger, et al. · Journal of Phytopathology · 60
Quantitative determination of the influence of adjuvants on foliar fungicide residues
2007 · Bert Ryckaert, Pieter Spanoghe, et al. · Crop Protection · 60
Potential Molecular Mechanisms behind the Ultra-High Dose Rate “FLASH” Effect
2022 · Eva Bogaerts, Ellina Macaeva, et al. · International Journal of Molecular Sciences · 53
PDF
A Systematic Assessment of Radiation Dose Enhancement by 5-Aza-2′-Deoxycytidine and Histone Deacetylase Inhibitors in Head-and-Neck Squamous Cell Carcinoma
2009 · Harlinde De Schutter, Marlies Kimpe, et al. · International Journal of Radiation Oncology*Biology*Physics · 52
Is There an Additional Value of 11C-Choline PET-CT to T2-weighted MRI Images in the Localization of Intraprostatic Tumor Nodules?
2012 · Laura Van den Bergh, Michel Koole, et al. · International Journal of Radiation Oncology*Biology*Physics · 41
From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial
2023 · Lisa De Cock, Cédric Draulans, et al. · Radiotherapy and Oncology · 39
Impact of Magnetic Resonance Imaging on Prostate Cancer Staging and European Association of Urology Risk Classification
2019 · Cédric Draulans, Wouter Everaerts, et al. · Urology · 39
The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo
2016 · Annelies Gonnissen, Sofie Isebaert, et al. · Oncotarget · 39
PDF
Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer
2020 · Cédric Draulans, Robin De Roover, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 37
PDF
DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer
2015 · Kirill Litovkin, Aleyde Van Eynde, et al. · PLoS ONE · 35
PDF
Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer
2014 · Kirill Litovkin, Steven Joniau, et al. · Journal of Cancer Research and Clinical Oncology · 34
The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells
2017 · Annelies Gonnissen, Sofie Isebaert, et al. · International Journal of Molecular Sciences · 32
PDF
Evaluating a Decision Aid for Patients with Localized Prostate Cancer in Clinical Practice
2008 · S. Isebaert, C. Van Audenhove, et al. · Urologia Internationalis · 31
Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus
2019 · Cédric Draulans, Robin De Roover, et al. · Radiotherapy and Oncology · 30
Works count: 134
Citation count: 2,666
H-index: 27
I10-index: 43
Year
Topic
Type